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Introduction: Tuberculosis, particularly multi-drug-resistant tuberculosis, is a major cause of
morbidity and mortality worldwide. To the best of our knowledge, however, no study to date
has  assessed the combined use of the four available drugs for tuberculosis treatment, which
is  an issue of great clinical relevance.
Objective: To determine whether the four-drug ﬁxed-dose combination is safer or more effec-
tive  than separate drugs for treatment of pulmonary tuberculosis.
Methods: A systematic review of the literature was performed in accordance with Preferred
Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Results: In pooled results from ﬁve randomized controlled trials with 3502 patients across
Africa, Asia, and Latin America, four-drug ﬁxed-dose combination therapy was no better
than  separate drugs therapy in terms of culture conversion after 2 and 6 months of treat-
ment.  There were no signiﬁcant differences between the groups in overall incidence of
adverse effects. However, the meta-analytic measure (log odds ratio) revealed that separate
drugs treatment had a 1.65 [exp (0.5) = 1.65] increased chance of gastrointestinal adverse
effects compared to four-drug ﬁxed-dose combination treatment.
Conclusions: The reviewed studies showed that four-drug ﬁxed-dose combination therapy
provides greater patient comfort by reducing the number of pills and the incidence of
gastrointestinal adverse effects, as well as simplifying pharmaceutical management at all
levels.
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ntroduction
uberculosis (TB) continues to be a major cause of morbid-
ty and mortality worldwide, with 9 million new cases of TB
iagnosed and 1.5 million TB-related deaths recorded glob-
lly in 2013. Approximately 95% of the estimated numbers of
B cases occur in low-income countries, with 82% of these
ases being concentrated in 22 countries, among which Brazil
anks 17th.1 This TB burden is increased by human immuno-
eﬁciency virus (HIV) infection, which impairs the immune
ystem and allows progression to active TB disease in large
umbers of people.2
Furthermore, the global burden of drug-resistant TB is
rowing. In 2010, an estimated 650,000 cases of drug-resistant
B were reported worldwide.3 Incidence of drug-resistant TB
as been on the rise in Brazil, according to data obtained in the
econd Brazilian National Survey on Anti-TB Drug Resistance
007–2008.4 In 2014, the Brazilian Ministry of Health delivered
48 GeneXpert instrument systems to all 92 municipalities
hat comprise the Rapid TB-Test Network, which covers all
razilian states. These instrument systems are capable of
iagnosing TB in 2 h, while simultaneously identifying the
ensitivity proﬁle to rifampicin, one of the main drugs for TB
reatment.5 Alongside the rising prevalence of drug-resistant
B, there has been an increase in the spread of cases due to
irect contact with drug-resistant TB patients. Consequently,
rug-resistant TB has become an epidemic itself, especially
n high-burden settings.6,7 Multidrug resistance is a further
hreat to TB control. Development of drug- or multi-drug-
esistant (MDR) TB is caused by inadequacies in treatment,
uch as in the number of drugs in the regimen to which the
acilli are susceptible, the dose or dosing frequency, the drug
uality, or the treatment adherence.3,8,9
Fixed-dose combinations (FDCs) of drugs for TB treatment
ave been advocated internationally to prevent the emer-
ence of drug resistance attributable to inappropriate drug
ntake.10,11 Use of FDCs can reduce the risk of an incor-
ect dosage, simplify drug procurement, and aid in ensuring
dherence without changing the drug dosage. In 2010, Brazil’s
ational TB Program altered their traditional anti-TB treat-
ent (2RHZ/RH regimen), which comprised rifampicin (R),
soniazid (H), and pyrazinamide (Z) for 2 months followed
y R and H for 4 months. The change followed a report by
he Second Brazilian National Survey on Anti-TB Drug Resis-
ance (2007–2008), which showed that primary resistance to
 or H + R had increased from 4.4% to 6.0% and from 1.1% to
.4%, respectively, compared to data from the First Brazilian
urvey (1995–1997). In the new 2RHZE/4RH regimen, a fourth
rug, ethambutol (E), was added to the intensive phase (ﬁrst 2
onths) of TB treatment. Capsules containing R and H, admin-
stered with Z tablets, were replaced by FDC tablets containing
, H, Z, and E. In the new formulation, H and Z were admin-
stered at lower doses compared to the traditional 2RHZ/RH
egimen. Pharmacological presentation of this scheme is a
ablet containing a FDC of four drugs: 150 mg  of R, 75 mg  of
, 400 mg  of Z, and 275 mg  of E. The 2RHZE/RH scheme is still
ecommended for children under 10 years of age.4
The basic treatment of TB with four drugs is used world-
ide, showing excellent effectiveness, particularly amongo l o g y 4 8 (2 0 1 7) 198–207 199
patients with good treatment adherence. With the addition
of a fourth drug, it is expected that treatment success will
improve, preventing any further increase in resistance to
H with or without R. FDC regimens have advantages such
as improved patient comfort and treatment adherence (by
reducing the number of pills) and simpliﬁed pharmaceutical
management at all levels.4 The aims of this new approach
were to increase treatment adherence and prevent drug
resistance.12
Over the years, problems have been found with the quality
of the 2RHZE/4RH regimen, such as a reduced bioavailability of
R, instability of the formulation, toxic/allergic AEs, and devel-
opment of resistance. Several studies have been conducted
to assess the bioavailability, acceptability, and microbiologi-
cal efﬁcacy of R and H, with or without Z, administered as
a FDC for daily or intermittent use.13–17 However, in patients
with newly diagnosed TB, the use of four drugs in a ﬁxed-
dose combination (4-FDC) in the ﬁrst 2 months of treatment
has not been assessed for safety and efﬁciency relative to the
administration of separate drugs (SDs).
To frame recent studies within the broader evidence base,
we systematically reviewed randomized clinical trials (RCTs)
that provided clinical data regarding the efﬁcacy and safety
of 4-FDC drugs in the treatment of pulmonary TB. This study
aimed to determine whether the administration of 4-FDC is
safer or more  effective than SD regimens for the treatment of
pulmonary TB.
Methods
A systematic review was conducted in accordance with
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines.18 The protocol for this review
was recorded on 23 May 2013 in the International Register of
Prospective Systematic Reviews (PROSPERO) under registra-
tion no. CRD42013003217.
Search  strategy  and  selection  criteria
Articles were searched in the following databases: Cumula-
tive Index to Nursing and Allied Health Literature (CINAHL
– http://www.cinahl.com), Cochrane Library (http://www.
update-software.com/cochrane), Latin American and
Caribbean Literature in Health Sciences (LILACS; http://
lilacs.bvsalud.org/), MEDLINE (http://www.nlm.nih.gov), Sci-
entiﬁc Electronic Library Online (SciELO; http://www.scielo.br),
Scopus (http://www.scopus.com), Web of Science (http://www.
webofknowledge.com), Science Direct (http://www.
sciencedirect.com), ExcerptaMedica Database (EMBASE;
http://www.embase.com), CAPES Theses Database, and
public domain internet databases (http://www.periodicos.
capes.gov.br). All databases were searched from inception
through 10 September 2013 for articles in English, French, and
Spanish. We  sought to compare results from RCTs involving
patients with newly diagnosed TB who were administered a
4-FDC or SD regimen in the ﬁrst 2 months of treatment for
pulmonary TB. Therefore, a search strategy was developed by
combining the following search terms: tuberculosis; treatment;
and rifampicin;  and isoniazid; and ethambutol;  and pirazinamide;
 i c r o200  b r a z i l i a n j o u r n a l o f m
and not HIV, as exploded Medical Subject Headings (MeSH)
and free-text terms. Additionally, abstracts from the follow-
ing conferences until September 2013 were searched: Union
World Conference on Lung Health, Interscience Conference on
Antimicrobial Agents and Chemotherapy, Society of General
Microbiology, British Thoracic Society, European Respiratory
Society, and the American Thoracic Society. Bibliographies of
all relevant articles were also reviewed.
Data  extraction  and  management
Two independent reviewers (GCL and EVS) and a third reviewer
(JSN) resolved any disagreements on selected studies. Efﬁcacy
and safety of the treatment were the primary and secondary
outcomes, respectively. Treatment outcomes were recorded
according to deﬁnitions adapted from those given in WHO
guidelines.19 Brieﬂy, treatment success was deﬁned as the
number of patients who were cured or who completed com-
bined treatment. Default was deﬁned as failure of the patient
to attend the healthcare service for over 30 consecutive days
after the scheduled return date. Safety was deﬁned as the
number of AEs.
The quality of studies was assessed with the Jadad scale.20
A predeﬁned data extraction form (in EXCEL) was used to
extract data from each study selected for review. The follow-
ing information was recorded: study characteristics, including
authors, setting, study design, and hospitalization; patient
characteristics, including age, population, availability of drug
susceptibility testing, sputum conversion and default rates at
the beginning and end of treatment, observed AEs, previous TB
regimens, HIV status, and other comorbidities; and treatment
characteristics, including the number of patients receiving 4-
FDC and SD regimens, and treatment outcomes.
Data  analysis
When possible, statistical calculations were performed with
the R software package, version 3.1.1.21 Because all evaluated
outcome measures were dichotomous, odds ratios (ORs) were
calculated, with the uncertainty of the result expressed by
the estimate of the 95% conﬁdence interval (CI) around this
measure. Individual studies were grouped by either the ﬁxed-
or random-effects method, depending on the results of the
test for homogeneity. Homogeneity among studies was evalu-
ated by the Cochran Q test, with p > 0.05 indicating statistically
signiﬁcant data homogeneity.
Results
Study  selection  results
The search strategy retrieved 438 potential articles (Fig. 1).
Two articles, one published in Mandarin and one in German,
were excluded due to language. One article was excluded
for failure to meet the criteria of an RCT. Eight articles were
screened as full-text articles, and ﬁve articles were sub-
sequently analyzed.14,22–25 All studies were conducted and
published in countries with a high incidence of TB. The b i o l o g y 4 8 (2 0 1 7) 198–207
ﬁve studies that were considered for analysis included 3502
patients across Africa, Asia and Latin America.
Study  and  patient  characteristics
Study and treatment characteristics are summarized in
Table 1. All studies were RCTs. Of the 3502 included patients,
2072 were men  (59.2%). Only three studies detailed the mean
patient age, with the result of 35 ± 15.3 years. In one study,
patients were randomly assigned to three groups (A, B, C):
patients in groups A and B were given 4-FDC, and patients
in group C were given SD formulations.25 Patients in the other
studies were randomized into two groups (4-FDC and SD). All
patients in the studies received the 4-FDC during the intensive
phase of treatment.
Two studies provided information regarding HIV status.22,24
In one study,24 77 of the 1168 patients (6.6%) were HIV positive.
In another included study,22 only six out of 1159 patients (0.5%)
were HIV positive (one in the FDC group, ﬁve in the SD group).
In four studies, clinical efﬁcacy was monitored by regular chest
X-rays.14,22,24,25
Two studies provided data from drug sensitivity tests.14,24
In one study,14 four patients in the FDC group and six patients
in the SD group had PZA-resistant bacilli. Two patients in the
SD group had EMB-resistant bacilli. In another study,24 1132
patients (573 FDC, 559 SD) were tested for drug sensitivity. Fully
sensitive organisms were identiﬁed in 508 FDC patients (88.2%)
and 497 SD patients (88.9%). Non-MDR, H-resistant isolates
were observed in 65 FDC patients (11.3%) and 62 SD patients
(11.1%).
Only one study evaluated or reported weight gain, a
decrease in the erythrocyte sedimentation rate, and an
increase in hemoglobin in the initial and continuation phases
of therapy.25 In another study, one patient in the FDC group
(1/51, 2%) experienced bacterial relapse after 5 months of suc-
cessful completion of the initial course of treatment.14
Adverse  events
Table 2 summarizes the AEs reported by the included stud-
ies. The most common AEs were gastrointestinal disorders
(nausea, vomiting), which were reported by all studies. How-
ever, dermatological, rheumatologic, and hepatic problems,
and even death, were cited. All studies found that the differ-
ence between the 4-FDC and SD groups in the overall number
of drug-related AEs was no longer signiﬁcant after general dis-
orders were excluded. Three studies reported patient death.
One study,24 reported eight deaths, which were most likely
(2/591 in FDC and 2/579 in SD group) or possibly due to TB
(2/591 in FDC and 2/579 in SD group). In another study, only
one death was reported, which was in the SD group.25 Bar-
tacek et al. reported 15 deaths (11 in FDC and 4 in SD group),
but only two of them (two hepatitis cases, both in FDC group)
were considered to be drug-related.22
One study reported less frequent muscle-joint effects dur-
ing the intensive phase of treatment in a patient receiving the
FDC regimen.23 Only one study evaluated patient acceptabil-
ity of medication, in terms of taste, number of tablets, and
problems with swallowing. The paper reported signiﬁcantly
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oFig. 1 – F
mproved patient acceptability of the regimen in the 4-FDC
roup.22
tudy  quality
o evaluate the methodological quality of included trials, a
adad scale based on three questions was used. Scores greater
han 3 are indicative of high-quality studies, and scores of 2
r less are indicative of low-quality studies.20 Three studies
ad a high quality score, and two studies were considered low
uality.
reatment  outcomes
 meta-analysis was developed for each variable in the study.
ested variables included the following: rates of sputum con-
ersion in the initial phase of treatment (assessed within 2
onths of treatment initiation), sputum conversion in the
nal phase of treatment, default, number of patients with AEs,
nd number of patients with gastrointestinal AEs. For each
ariable, the following null hypothesis was tested:0. The event of interest (variable) has the same chance of
ccurring in both treatment groups (4-FDC and SD).iagram.
For the analysis of sputum conversion in the initial phase
of treatment (≤2 months), all ﬁve studies collected related
data and were considered in the analysis. The ﬁxed-effects
model was chosen because heterogeneity was not identiﬁed
(p = 0.3169). The null hypothesis was not rejected (p = 0.4922),
suggesting that there was no statistical evidence that the rate
of sputum conversion in the initial phase of treatment dif-
fered between treatment groups. A forest plot (Fig. 2) showed
that the 95% CI range for the log OR contained zero (log
OR: −0.09, 95% CI: −0.37 to 0.18), indicating that the OR
between treatments was statistically equal to one. Therefore,
meta-analysis results did not reveal a statistically signiﬁcant
difference between 4-FDC and SD treatments in terms of the
rate of sputum conversion in the initial phase of treatment.
For the analysis of sputum conversion in the ﬁnal phase
of treatment, one study,25 did not collect related data and
was excluded from the analysis. The ﬁxed-effects model was
chosen because heterogeneity was not identiﬁed (p = 0.98).
The null hypothesis was not rejected (p = 0.5037), suggesting
that there was no statistical evidence that sputum conversion
in the ﬁnal phase of treatment differed between treatment
groups. A forest plot (Fig. 3) showed that the 95% CI range for
the log OR contained zero (log OR: 0.14, 95% CI: −0.27 to 0.54),
indicating that the OR between treatments was statistically
equal to one. Therefore, meta-analysis results did not reveal a
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Table 1 – Characteristics of randomized clinical trials, comparing FDC with SD regimens for treatment of TB, that were





Eligibility criteria Study treatments,
initial phase (2 mo)a
Jadad scale
Su, 200214 105 Taiwan 6 18+ yr with active
pulmonary TB
conﬁrmed by smear or
culture and no history
of previous treatment
for TB
FDC = INH 50 mg + RIF
120 mg + PZA
250 mg + EMB 1200 mg;
SD = INH 300 mg + RIF
450 mg + PZA




360 Indonesia 36 Sputum positive, weight




FDC = INH 75 mg + RIF
150 mg + PZA
400 mg + EMB 275 mg;
SD = INH 300 mg + RIF
450 mg + PZA




293 Pakistan 6 15–55 yr, sputum
positive, no kidney, liver
or heart disease, and
not pregnant
Group A (FDC) = INH
75 mg + RIF 120 mg + PZA
350 mg + EMB 250 mg;
Group B (FDC) = INH
60 mg + RIF 120 mg + PZA
300 mg + EMB 225 mg;
Group C (SD) = INH
100 mg + RMP 450 mg









21  15+ yr, ≥2 positive
sputum samples or 1
positive sputum sample
and a chest X-ray, and
received treatment for
TB for ≤1 mo
FDC = INH 75 mg + RIF
150 mg + PZA
400 mg + EMB 275 mg;
SD = INH 75 mg + RIF
150 mg + PZA




1585 Africa, Asia, and
Latin America
30  New diagnosis of TB
conﬁrmed by sputum
smear-positive, received






FDC  = INH 75 mg + RIF
150 mg + PZA
400 mg + EMB 275 mg;
SD = INH 100 mg + RIF
150 mg + PZA
400 mg + EMB 400 mg
3
EMB, ethambutol; FDC, ﬁxed-dose combination; INH, isoniazid; PZA, piraz









–0.04 [ –0.45 , 0.37 ]
 0.10 [ –0.33 , 0.52 ]
–1.34 [ –3.49 , 0.80 ]
–0.66 [ –1.43 , 0.11 ]
–0.87 [ –3.03 , 1.29 ]
–0.09 [ –0.37 , 0.18 ]
Fig. 2 – Forest plot for rate of sputum conversion in the
initial phase of treatment (≤2 months after start of
treatment).inomide; RIF, rifampin; SD, single dose; TB, tuberculosis.
 and The European Union recommendations.
statistically signiﬁcant difference between 4-FDC and SD treat-
ments in terms of sputum conversion in the ﬁnal phase of
treatment.
For the analysis of default, one study,25 did not collect
related data. As it was not possible to contact the authors,
this study was excluded from the analysis. The ﬁxed-effects
model was chosen because heterogeneity was not identiﬁed
(p = 0.0775). The null hypothesis was not rejected (p = 0.9092),
suggesting that there was no statistical evidence that the
default differed between treatment groups. A forest plot (Fig. 4)
showed that the 95% CI range for the log OR contained zero
(log OR: 0.05, 95% CI: −0.82 to 0.92), indicating that the OR
between treatments was statistically equal to one. Therefore,
meta-analysis results did not reveal a statistically signiﬁcant
difference between 4-FDC and SD treatments in terms of
default.
For the analysis of the number of patients with AEs, two
studies,14,23 did not collect related data and were excluded








































Table 2 – Adverse events (AEs) reported in the included studies.
Study No. of patients in
FDC/SD group
AEs  (no. of patients)
in FDC group
AEs  (no. of patients)
in SD group
Default Relapse TB drug-related
death
Su, 200214 26/25 Hyperuricemia (8),
skin itching (4), skin










































































4/591 FDC, 4/579 SD








 0.14 [ –0.36 , 0.63 ]
 0.32 [ –0.75 , 1.38 ]
 0.01 [ –0.94 , 0.96 ]
–0.04 [ –4.00 , 3.92 ]
 0.14 [ –0.27 , 0.54 ]







 0.17 [ –0.32 , 0.66 ]
–0.14 [ –0.42 , 0.14 ]
 0.90 [  0.19 , 1.61 ]
 0.24 [ –0.32 , 0.79 ]










0.63 [ –0.37 , 1.63 ]
0.34 [ –0.17 , 0.84 ]
0.31 [ –0.50 , 1.12 ]
0.61 [  0.18 , 1.03 ]
2.65 [ –0.30 , 5.61 ]
0.50 [  0.22 , 0.79 ]of therapy.
the authors of these studies. The random-effects model was
chosen because heterogeneity was identiﬁed (p = 0.0246 and
I2 = 75.85%). The null hypothesis was not rejected (p = 0.4091),
suggesting that there was no statistical evidence that the
number of patients with AEs differed between treatment
groups. A forest plot (Fig. 5) showed that the 95% CI range
for the log OR contained zero (log OR: 0.24, 95% CI: −0.32 to
0.79), indicating that the OR between treatments was statis-
tically equal to one. Therefore, meta-analysis results did not
reveal a statistically signiﬁcant difference between 4-FDC and
SD treatments in terms of the number of patients with AEs.
For the analysis of the number of patients with gastroin-
testinal AEs, all ﬁve studies collected related data and were
included in the analysis. The ﬁxed-effects model was chosen
because heterogeneity was not identiﬁed (p = 0.5656). The null
hypothesis was rejected (p = 0.0006), suggesting that there was
statistical evidence that the chance of occurrence of gastroin-
testinal AEs differed between treatment groups. A forest plot
(Fig. 6) showed that the 95% CI range for the log OR did not con-
tain zero (log OR: 0.50, 95% CI: 0.22–0.79), indicating that the OR
between treatments was statistically different from one. The
meta-analytic measure (log OR) revealed that the SD treatment
was associated with a 1.65-fold [i.e., exp (0.5) = 1.65] greater








–2.20 [ –4.29 , –0.12 ]
 1.63 [ –0.54 ,  3.80 ]
 0.70 [ –1.82 ,  3.21 ]
 0.16 [ –1.02 ,  1.34 ]
 0.05 [ –0.82 ,  0.92 ]
Fig. 4 – Forest plot for default.Fig. 6 – Forest plot for number of patients with
gastrointestinal adverse effects.
Discussion
On the basis of the pooled results of the RCTs, 4-FDC therapy
failed to show beneﬁts over the SD regimen in culture conver-
sion after 2 or 6 months of treatment. However, the results
did not demonstrate complete inferiority of FDC compared
to SD regimens when using the strict deﬁnition applied in
this review. Except for one study that identiﬁed better treat-
ment satisfaction,22 none of the included studies identiﬁed
improved patient adherence among TB patients treated with
4-FDC compared to those treated with SD formulations.
Most of the side effects that were reported by the studies in
this review were not considered serious and could be managed
through symptomatic palliation in both groups of patients
(4-FDC and SD). Even in a study that reported 176 patients
(86%) with at least one AE associated with treatment, only
two patients abandoned the study because of AEs.26 Gastroin-
testinal side effects, such as diarrhea and malabsorption, can
hinder achievement of optimal blood concentrations of anti-
TB drugs in patients co-infected with HIV.27 This observation
suggests that 4-FDC therapy, by causing fewer gastrointestinal
side effects, would beneﬁt co-infected patients. Some patients

























































therapy is an important evolution in TB treatment. Theseb r a z i l i a n j o u r n a l o f m i c 
eported stopping medication because of AEs,28 whereas oth-
rs indicated that they were not informed about side effects
r what to do to counter them.29–31 No ophthalmic AEs (ocu-
ar toxic effects) were reported that could be associated with
he new drug (EMB). Retrobulbar optic neuritis, the main AE to
MB,  is rare in the doses and exposure times commonly used
or TB treatment.32
Despite the potential for providing the highest level of
vidence in therapeutic intervention research, RCTs have
een criticized because of their limited generalizability. RCTs
re often conducted under optimal medical care and may
nderestimate the potential beneﬁt of using 4-FDC formula-
ions to enhance adherence in settings where malpractice or
nmonitored therapies are common. Important differences
n adherence have been found in many  RCTs.33 Therefore,
ragmatic clinical trials, which are conducted in a way
hat more  closely resembles typical clinical practice, may be
ore appropriate to obtain a better estimate of treatment
ffectiveness.34,35
At the beginning of 2013, a systematic review was pub-
ished in Canada to evaluate the risk of treatment failure
r disease relapse, acquired drug resistance, bacterial con-
ersion after 2 months of treatment, AEs, adherence, and
reatment satisfaction associated with treatment of active TB
sing FDC or SD formulations.36 This study concluded that,
lthough FDC formulations simplify TB therapy, the current
vidence did not indicate that these formulations improve
reatment outcomes among patients with active TB. How-
ver, that systematic review included studies of both four-drug
nd two-drug combinations and, therefore, differs from the
resent one in the number of retrieved articles. These differ-
nces justify the need for a revision to compare precisely the
ffect of 4-FDC versus SD formulations.
The World Health Organization has recommended 4-FDC
reatments since 1999. Combined treatments prevent drug
election by the patient (monotherapy) by providing all of the
rugs in the same tablet.12,34,35,37 Due to their simpliﬁed and
tandardized nature, 4-FDC regimens facilitate dosage calcu-
ation and prevent prescription errors. However, one of the
ost relevant features of 4-FDC formulations, the prevention
f drug resistance, was not addressed in those studies. Nev-
rtheless, based on their similar efﬁcacies, user-friendliness,
ower costs, and operational and logistical advantages, gen-
ralized use of 4-FDC formulations should continue to be
ecommended.
One limitation of this meta-analysis is that the included
tudies did not investigate adherence to the prescribed
reatment. Moreover, the impact of the Directly Observed
reatment Short-Course (DOTS) strategy on the outcomes of
B treatment was not assessed, which resulted in less pre-
ise estimates. Another limitation is the inconsistency in
scertainment of the time of relapse in the different studies;
ecause of the heterogeneous methods, we  did not pool the
tudy results for this variable. We could not assess mortal-
ty as an outcome because this term was deﬁned differently
n the studies (all-cause vs. TB-speciﬁc mortality), measured
ver different follow-up periods and, in some studies, was
ot reported or not attributed to the treatment group. Finally,
mall differences in drug concentrations existed between
tudies. Regardless of these limitations, this systematic reviewo l o g y 4 8 (2 0 1 7) 198–207 205
has several strengths. Lack of signiﬁcant heterogeneity of the
estimates of sputum conversion in the initial and ﬁnal phases
of therapy and of default in the different trials permitted
pooling and increased the precision of our results regarding
treatment efﬁcacy.
By the end of 2009, Brazil was the only country with a
high burden of TB to use a three-drug treatment regimen.
Despite a free-of-charge treatment, the mean default rate was
approximately 9.3% and reached 14% in some states.38 In a
Brazilian descriptive study based on prospective data obtained
from the medical records of adult TB patients treated with
4-FDC tablets, the obtained cure rates were similar to those
obtained with SD treatments. However, the rate of treatment
abandonment was much higher (17.5%) than that considered
appropriate (≤5%). These data strongly suggest that the use
of FDC tablets does not have a signiﬁcant impact on adher-
ence to treatment. Therefore, measures to improve adherence,
such as supervised treatment, should not be neglected.11 In
addition, studies conducted in Brazil have demonstrated the
association between lower rates of treatment abandonment
and supervised treatment.39–41
The new 4-FDC regimen was expected to result in lower
default rates and higher effectiveness of treatment by pre-
venting drug selection and the further appearance of resistant
pathogens. To ensure success of the new treatment, better
care and attention to patients, including expansion of DOTS
strategy in Brazil, are needed. In the analysis of the Brazil-
ian case, Zuim et al. said that the success of TB control,
as with other health problems, goes beyond the availabil-
ity of diagnostic tests and drugs, requiring measures related
to the establishment of links between health profession-
als and health system users.42 Corroborating that idea, in
Taiwan, a prospective RCT was conducted using the DOTS
strategy to compare the safety and efﬁcacy of two types of
anti-TB regimens (FDC versus SD) for pulmonary TB treat-
ment. No signiﬁcant difference in safety or efﬁcacy was
found between the groups when the DOTS strategy was
used.43
Of the 22 high TB-burden countries, Brazil is the last
to adopt the 4-FDC regimen.38 Gemal et al. stated that the
maintenance of low resistance rates in Brazil compared to
other countries might be because medicines are distributed
exclusively by public health services, in accordance with the
logistics system of the Ministry of Health.44
Conclusion
Among the ﬁve variables, only gastrointestinal AEs differed
signiﬁcantly between treatments (SD and 4-FDC), with a meta-
analytic measurement equal to 0.50 and a p-value of less
than 0.001. All of the studies showed that 4-FDC therapy
provides greater patient comfort by reducing the number of
pills and the incidence of gastrointestinal AEs, which are
the most-reported side effects, in addition to simplifying
pharmaceutical management at all levels. Therefore, 4-FDCtherapies should be implemented with simultaneous phar-
macovigilance studies and pragmatic trial designs to simulate
real-world clinical practice, associated with new technologies
 i c r o
r206  b r a z i l i a n j o u r n a l o f m
and measures to establish links between health professionals
and health system users.
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